Sparsentan Fails In Phase III FSGS Study, But Travere Assessing Path To Approval

No Readthrough Likely In Confirmatory IgAN Trial

 
• By Mandy Jackson
Kidneys made of pills on blue background
Confirmatory data in IgAN are expected in Q4 of 2023 • Source: Shutterstock

More from Clinical Trials

More from R&D